These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38041716)

  • 1. CNS-Active p38α MAPK Inhibitors for the Management of Neuroinflammatory Diseases: Medicinal Chemical Properties and Therapeutic Capabilities.
    Valipour M; Mohammadi M; Valipour H
    Mol Neurobiol; 2024 Jul; 61(7):3911-3933. PubMed ID: 38041716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors.
    Astolfi A; Iraci N; Manfroni G; Barreca ML; Cecchetti V
    ChemMedChem; 2015 Jun; 10(6):957-69. PubMed ID: 26012502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p38α MAPK and Type I Inhibitors: Binding Site Analysis and Use of Target Ensembles in Virtual Screening.
    Astolfi A; Iraci N; Sabatini S; Barreca ML; Cecchetti V
    Molecules; 2015 Aug; 20(9):15842-61. PubMed ID: 26334265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D-QSAR and molecular docking studies on fused pyrazoles as p38α mitogen-activated protein kinase inhibitors.
    Lan P; Huang ZJ; Sun JR; Chen WM
    Int J Mol Sci; 2010 Sep; 11(9):3357-74. PubMed ID: 20957100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status and future prospects of p38α/MAPK14 kinase and its inhibitors.
    Madkour MM; Anbar HS; El-Gamal MI
    Eur J Med Chem; 2021 Mar; 213():113216. PubMed ID: 33524689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The p38alpha mitogen-activated protein kinase as a central nervous system drug discovery target.
    Borders AS; de Almeida L; Van Eldik LJ; Watterson DM
    BMC Neurosci; 2008 Dec; 9 Suppl 2(Suppl 2):S12. PubMed ID: 19090985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular modeling of p38α mitogen-activated protein kinase inhibitors through 3D-QSAR and molecular dynamics simulations.
    Chang HW; Chung FS; Yang CN
    J Chem Inf Model; 2013 Jul; 53(7):1775-86. PubMed ID: 23808966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of potent p38α MAPK inhibitors through a funnel like workflow combining in silico screening and in vitro validation.
    Astolfi A; Kudolo M; Brea J; Manni G; Manfroni G; Palazzotti D; Sabatini S; Cecchetti F; Felicetti T; Cannalire R; Massari S; Tabarrini O; Loza MI; Fallarino F; Cecchetti V; Laufer SA; Barreca ML
    Eur J Med Chem; 2019 Nov; 182():111624. PubMed ID: 31445234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorescence polarization-based assays for detecting compounds binding to inactive c-Jun N-terminal kinase 3 and p38α mitogen-activated protein kinase.
    Ansideri F; Lange A; El-Gokha A; Boeckler FM; Koch P
    Anal Biochem; 2016 Jun; 503():28-40. PubMed ID: 26954235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and anti-neuroinflammatory activity of lactone benzoyl hydrazine and 2-nitro-1-phenyl-1h-indole derivatives as p38α MAPK inhibitors.
    Cheng B; Lin Y; Kuang M; Fang S; Gu Q; Xu J; Wang L
    Chem Biol Drug Des; 2015 Nov; 86(5):1121-30. PubMed ID: 25960125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.
    Muth F; Günther M; Bauer SM; Döring E; Fischer S; Maier J; Drückes P; Köppler J; Trappe J; Rothbauer U; Koch P; Laufer SA
    J Med Chem; 2015 Jan; 58(1):443-56. PubMed ID: 25475894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.
    Goettert M; Schattel V; Koch P; Merfort I; Laufer S
    Chembiochem; 2010 Dec; 11(18):2579-88. PubMed ID: 21108268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-crystal structure determination and cellular evaluation of 1,4-dihydropyrazolo[4,3-c] [1,2] benzothiazine 5,5-dioxide p38α MAPK inhibitors.
    Bartolini D; Bührmann M; Barreca ML; Manfroni G; Cecchetti V; Rauh D; Galli F
    Biochem Biophys Res Commun; 2019 Apr; 511(3):579-586. PubMed ID: 30824186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorescence polarization binding assay to develop inhibitors of inactive p38alpha mitogen-activated protein kinase.
    Munoz L; Selig R; Yeung YT; Peifer C; Hauser D; Laufer S
    Anal Biochem; 2010 Jun; 401(1):125-33. PubMed ID: 20175985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human p38α mitogen-activated protein kinase in the Asp168-Phe169-Gly170-in (DFG-in) state can bind allosteric inhibitor Doramapimod.
    Suplatov D; Kopylov K; Sharapova Y; Švedas V
    J Biomol Struct Dyn; 2019 May; 37(8):2049-2060. PubMed ID: 29749295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comprehensive Structural Overview of p38α Mitogen-Activated Protein Kinase in Complex with ATP-Site and Non-ATP-Site Binders.
    Astolfi A; Manfroni G; Cecchetti V; Barreca ML
    ChemMedChem; 2018 Jan; 13(1):7-14. PubMed ID: 29210532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ).
    Bachstetter AD; Xing B; de Almeida L; Dimayuga ER; Watterson DM; Van Eldik LJ
    J Neuroinflammation; 2011 Jul; 8():79. PubMed ID: 21733175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of naphthyl-N-acylhydrazone p38α MAPK inhibitors with in vivo anti-inflammatory and anti-TNF-α activity.
    Freitas RHCN; Cordeiro NM; Carvalho PR; Alves MA; Guedes IA; Valerio TS; Dardenne LE; Lima LM; Barreiro EJ; Fernandes PD; Fraga CAM
    Chem Biol Drug Des; 2018 Feb; 91(2):391-397. PubMed ID: 28815968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.
    Cumming JG; Debreczeni JÉ; Edfeldt F; Evertsson E; Harrison M; Holdgate GA; James MJ; Lamont SG; Oldham K; Sullivan JE; Wells SL
    J Med Chem; 2015 Jan; 58(1):278-93. PubMed ID: 25255283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding mode.
    Wrobleski ST; Lin S; Dhar TG; Dyckman AJ; Li T; Pitt S; Zhang R; Fan Y; Doweyko AM; Tokarski JS; Kish KF; Kiefer SE; Sack JS; Newitt JA; Witmer MR; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2013 Jul; 23(14):4120-6. PubMed ID: 23746475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.